GlassScriptPhysician profile
Bethany M Stern
NPI 1801331152
$1,647.77
in general payments reported to CMS, 2019-2025
27 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.90 · 2022: $89.28 · 2023: $395 · 2024: $547 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.88 | 2023-2025 | |
| Novo Nordisk INC | $223.85 | 2024-2025 | Wegovy, Sogroya |
| Tolmar, INC. | $192.20 | 2023-2025 | Fensolvi |
| Ascendis Pharma Endocrinology INC | $136.56 | 2024-2025 | Skytrofa |
| Tris Pharma INC | $64.02 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $63.41 | 2022-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $63.13 | 2021-2023 | Arexvy, Bexsero, Shingrix |
| Azurity Pharmaceuticals, INC. | $55.68 | 2024-2025 | Triptodur, Alvesco |
| Dexcom, INC. | $47.57 | 2022-2023 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $47.43 | 2024-2025 | |
| Alk-Abello, INC | $44.43 | 2025 | Neffy |
| Kyowa Kirin, INC. | $43.71 | 2023-2024 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $40.38 | 2024-2025 | |
| Beta Bionics, INC. | $40.34 | 2024 | Ilet Bionic Pancreas |
| Corium, LLC | $40.02 | 2023 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $37.37 | 2023-2024 | Valtoco |
| Xeris Pharmaceuticals, INC. | $36.94 | 2023 | Gvoke Hypopen |
| Sobi, INC | $31.96 | 2023 | |
| Sanofi Pasteur INC. | $29.90 | 2022-2023 | |
| Phadia US INC. | $27.58 | 2024 | Immunocap |
| Ironshore Pharmaceuticals INC. | $23.79 | 2024 | |
| Alexion Pharmaceuticals, INC. | $21.68 | 2023 | Strensiq |
| Tandem Diabetes Care, INC. | $20.81 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $20.68 | 2022 | |
| Convatec INC. | $18.00 | 2022 | |
| Noven Therapeutics, LLC | $16.64 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $14.81 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.